• The corporate DAT movement has gained visibility as public companies increasingly treat bitcoin and other digital assets as strategic balance-sheet holdings rather than short-term speculative instruments
• MindWave provides a secure and compliant gateway to digital assets through insured custody solutions, AI-enabled yield strategies and transparent reporting systems.
• The company’s institutional positioning is strengthened by its live bitcoin treasury activity.

As bitcoin moves deeper into corporate finance, the central question for many companies is no longer whether digital assets belong on the balance sheet but rather how they can be held, reported and deployed responsibly. MindWave Innovations (NYSE American: APUS) is positioning itself around that challenge as a digital asset and technology company focused on institutional-grade treasury infrastructure, combining insured custody solutions, AI-enabled yield strategies and transparent reporting systems for the digital asset economy.

The corporate Digital Asset Treasury, or DAT, movement has gained visibility as public companies increasingly treat bitcoin and other digital assets as strategic balance-sheet holdings rather than short-term speculative instruments. Research has described the DAT market as an emerging category of companies built around digital asset accumulation and treasury strategy, while earlier public-company examples such as Strategy and Metaplanet helped popularize bitcoin-centered treasury models.

That momentum has also exposed the practical barriers facing corporate finance teams. A digital asset treasury strategy requires more than buying bitcoin. Companies must address custody, accounting treatment, tax considerations, reconciliation, transaction approvals, volatility, audit controls and more. For example, BitGo’s crypto treasury management guidance notes that treasury management includes custody, key management, approvals, accounting, tax, audit support and counterparty controls, while Cozen O’Connor has emphasized the role of boards and management teams in aligning digital asset decisions with risk management and disclosure obligations.

Regulatory and accounting developments are also helping shape the environment for more institutional participation. The Financial Accounting Standards Board’s ASU 2023-08 requires certain crypto assets to be measured at fair value each reporting period, with changes reflected in net income, creating a clearer accounting framework for companies that hold assets such as Bitcoin. In addition, SEC’s Staff Accounting Bulletin No. 122 rescinded earlier SAB 121 guidance on safeguarding crypto assets, further signaling that digital asset accounting and custody rules continue to evolve.

MindWave’s platform is designed to respond to that institutional gap. MindWave provides a secure and compliant gateway to digital assets through insured custody solutions, AI-enabled yield strategies and transparent reporting systems. That combination is important because corporate adoption depends not only on asset exposure but also on the ability to demonstrate that treasury activity is documented and aligned with the expectations of directors, auditors and shareholders.

The company’s broader MindWaveDAO platform extends that treasury model into a blockchain-enabled ecosystem. MindWaveDAO describes itself as a decentralized autonomous organization building financial infrastructure that combines traditional finance security and compliance with blockchain transparency and efficiency. Its ecosystem is powered by the NILA token, which the platform says enables staking and access to financial products across the network.

A notable component of the ecosystem is MindWaveDAO’s Real-World Asset (RWA) framework, which is designed to bring traditional assets onto blockchain rails through tokenization. According to the company, the platform seeks to connect real-world value with decentralized finance by enabling assets such as real estate, commodities and other income-generating investments to participate in a more transparent and accessible digital environment. The initiative reflects a broader industry trend toward tokenized assets, a market many analysts view as one of the most significant long-term opportunities within blockchain-based finance.

By incorporating RWA infrastructure alongside digital asset treasury services, MindWaveDAO is positioning its ecosystem around both crypto-native and traditional asset classes. That approach expands the platform’s potential utility beyond bitcoin treasury management, creating additional pathways for yield generation, capital deployment and asset participation within the broader network.

A central component of the platform is the MindWave AI Yield Engine, which the company describes as a self-learning system that analyzes digital asset market data, identifies opportunities and mitigates risks in real time. For corporations considering bitcoin treasury strategies, this type of structure points to a broader evolution in DAT models: the move from passive holding toward actively managed infrastructure intended to support risk controls, yield generation and capital efficiency.

MindWaveDAO also presents NILA as a utility layer within the ecosystem. The company’s NILA token page states that NILA functions as the native gas token for its MindChain Layer 2 network and is used for staking tied to yield generated by the AI-powered engine. The same page describes NILA as deeply integrated into the MindWaveDAO ecosystem, connecting transaction utility, staking and platform participation.

The company’s institutional positioning is strengthened by its live bitcoin treasury activity. In December 2025, Apimeds Pharmaceuticals and MindWave Innovations announced the closing of up to $100 million PIPE financing and the activation of 1,000 bitcoin to power an AI-driven yield generation strategy. That announcement is significant because it frames MindWave’s model as more than a conceptual platform; it identifies an operating bitcoin position connected to a stated treasury and yield strategy.

The public-company structure also matters. Apimeds announced its merger with MindWave Innovations as a transaction combining Apimeds’ biotechnology portfolio with MindWave’s AI-driven bitcoin treasury, digital asset yield generation and NILA-powered ecosystem. In the DAT market, that type of public-market access can provide investors with exposure to digital asset treasury strategies through traditional equity channels, while also bringing the scrutiny and disclosure expectations associated with public companies.

For institutional adopters, the most important value proposition may be execution. Companies interested in holding bitcoin must satisfy internal controls, satisfy board oversight, manage custody risk, prepare financial statements and explain strategy to investors. MindWave’s model speaks directly to those needs by pairing custody and reporting infrastructure with AI-driven treasury functions and tokenized ecosystem utility.

As the DAT market matures, the winning models are likely to be those that can bridge crypto-native opportunity with institutional discipline. MindWave is attempting to occupy that middle ground by connecting public-market structure, live bitcoin holdings, tokenized real-world asset infrastructure, AI-driven yield capabilities, custody-focused controls and NILA-based ecosystem participation. In doing so, the company reflects the next stage of corporate bitcoin treasury adoption: not simply adding bitcoin to the balance sheet but building the infrastructure needed to manage it at scale.

For more information, visit the company’s website at www.MindWaveDAO.com

NOTE TO INVESTORS: The latest news and updates relating to APUS are available in the company’s newsroom at https://ibn.fm/APUS

• VERAXA is advancing a diversified oncology pipeline spanning monoclonal antibodies, antibody-drug conjugates, bispecific ADCs and proprietary BiTAC-based therapeutic formats across multiple cancer indications.
• The company’s proprietary BiTAC platform is designed to conditionally activate therapeutic activity at tumor sites, with the goal of improving target specificity while reducing off-tumor toxicity.
• Through its focus on ADCs and TCEs, VERAXA is positioned within two rapidly growing segments of the global oncology therapeutics market.
• Via selected partnerships, VERAXA aims to contribute value to developments in complementary therapeutic sectors such as radioimmunoconjugates (“RICs”) and antibody-oligonucleotide conjugates (“AOCs”).

VERAXA Biotech has successfully concluded a business combination with Voyager Acquisition Corp. (NASDAQ: VACH) and began trading on the NASDAQ Capital Market under the ticker symbol ‘VRXA’ on June 11, 2026.

VERAXA Biotech (NASDAQ: VRXA) is a biotechnology company focused on the discovery and development of a new generation of antibody-based therapeutics for the treatment of solid tumors. VERAXA’s vision is to deliver the next wave of smart cancer therapies with curative potential and improved safety profiles.

The company is building a pipeline that includes dual-targeting antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”) predominantly based on its patented BiTAC concept. This concept is designed to improve the precision, safety, and effectiveness of cancer treatments. Through its focus on potentially first-in-class conditionally active ADC and TCE platforms, VERAXA is positioned within two rapidly growing segments of the global oncology therapeutics market.

The biopharma industry is increasingly focusing on enhancing the therapeutic window of next-generation ADCs and TCEs by refining their tumor selectivity, conditional activation, and dose optimization. This shift—driven by clinical data demonstrating improved safety profiles and the potential for higher, more effective dosing—reflects a broader movement toward safer, more tolerable, and patient-friendly cancer therapies, ultimately aiming to unlock the full potential of these modalities especially in solid tumor settings.

VERAXA is headquartered in Zurich, Switzerland, with its R&D hub located in Heidelberg, Germany.

Pipeline

Central to VERAXA’s strategy is the application of its proprietary technology concept BiTAC (Bi-targeted Tumor-Associated Cytotoxicity), which enables the generation of conditionally active, AND-gated therapeutic candidates that precisely target cancer cells while leaving healthy cells intact. VERAXA is currently advancing a pipeline of early development programs with a focus on solid tumors. The most advanced program, a BiTAC-TCE targeting EpCAM and another tumor antigen has recently entered preclinical development. More detailed information on these early-stage assets is expected to emerge in the months following the NASDAQ listing.

VX-A901

VX-A901, a clinical-stage, monoclonal antibody therapy targeting FLT3 for the treatment of acute myeloid leukemia (“AML”) is currently VERAXA’s most-advanced program.

The antibody is designed to enhance antibody-dependent cellular cytotoxicity (“ADCC”), a mechanism that helps direct immune cells against cancer cells.

The program is intended to address the need for additional treatment options for elderly AML patients or patients who are not eligible for intensive chemotherapy and stem cell transplantation. VX-A901 has a distinct and complementary mechanism of action, independent of the patient’s FLT3 mutation status and could be combined with first-line therapy. Phase I results show that VX-A901 was safe and well tolerated in AML patients, with promising signs of monotherapy efficacy observed in heavily pre-treated patients. VERAXA has decided to out-license the future development and commercialization of the program due to the increasing focus on AND-gated modalities for the treatment of solid tumor indications.

BiTAC Platform

BiTAC (Bi-targeted Tumor-Associated Cytotoxicity) is VERAXA’s proprietary underlying concept of a new generation of dual-targeting antibodies with enhanced safety and efficacy characteristics. Unlike conventional bispecific antibodies that combine two target specificities within a single molecule, BiTAC splits the therapeutic candidate into two complementary molecules.

Any therapeutic effect is activated only when both molecules localize on the same tumor cell. VERAXA is applying this architecture to both TCE and ADC development programs with the goal of improving tumor selectivity, reducing damage to healthy tissues and thereby expanding the safety-to-efficacy ratio (therapeutic index).

Initial data from VERAXA’s most advanced BiTAC-TCE program were presented at the recent American Association for Cancer Research (“AACR”) Annual Meeting 2026 in San Diego, CA.  VERAXA’s BiTAC-TCE candidate performed as intended, attacking cancer cells featuring both target molecules while sparing cells expressing just one of these targets. In vivo data demonstrated a superior safety profile and matching efficacy compared to a conventional TCE, pointing to the possibility of a significantly improved therapeutic index.

Other ADC Technologies

VERAXA has developed a suite of technologies based on their proprietary biorthogonal click chemistry to innovate industry-leading ADC therapeutics. This includes a proprietary hydrophilic payload-linker platform, utilizing tumor-selective linkers, and glycan engineering-based click conjugation to site-specifically attach the payload to the antibody. Furthermore, the payload platform includes a proprietary prodrug approach of highly potent toxins, also based on tumor-selective activation. Through the combination of these technologies, VERAXA’s ADCs display favorable pharmacokinetics and offer an opportunity to enhance the safety-to-efficacy ratio of current ADCs. Initial data from VERAXA’s most advanced ADC program were presented at the recent American Association for Cancer Research (“AACR”) Annual Meeting 2026 in San Diego, CA.

Market Opportunity

VERAXA’s development strategy is centered on antibody-drug conjugates and bispecific T cell engagers, two areas of oncology therapeutics that have attracted significant industry attention due to their potential to improve treatment precision, efficacy, and safety. As the company advances programs across both categories, it is operating within markets that are expected to experience substantial long-term growth and deal activity.

The global antibody-drug conjugates market was valued at approximately $12.26 billion in 2024 and is projected to reach approximately $32.11 billion by 2033, according to Grand View Research, representing a compound annual growth rate of 10.49% from 2025 through 2033. The firm attributes this growth to increasing cancer prevalence and growing demand for targeted therapies designed to improve efficacy while reducing systemic toxicity.

According to Precedence Research, the global bispecific antibodies market is estimated at approximately $17.99 billion in 2025 and is projected to reach approximately $603.13 billion by 2035, representing a compound annual growth rate of 42.08% from 2025 through 2034.

Leadership Team

Christoph Antz, Ph.D., Chief Executive Officer and Co-Founder, is an experienced life sciences executive and former venture capital manager with expertise spanning drug development, diagnostics and scientific instrumentation. Prior to co-founding VERAXA, he served as managing director of Acousia Therapeutics and Luxendo, where he helped lead companies focused on inner-ear therapeutics and advanced microscopy technologies.

Torsten Bürgermeister, Chief Financial Officer, brings more than 20 years of finance and business development experience across life science and technology companies. Before joining VERAXA, he held leadership positions with Molecular Health, BASF Pharma, Techem Energy Services and Colt Telecom, and holds a diploma in business administration from DHBW Mannheim.

Rick Austin, Ph.D., Chief Scientific Officer, has extensive experience in oncology drug discovery and T-cell engager development. Prior to joining VERAXA, he served as vice president of research at Harpoon Therapeutics and previously held scientific leadership positions at Amgen and Tularik, contributing to multiple tumor immunology programs, IND filings and first-in-human studies while authoring more than 25 peer-reviewed publications and contributing to 12 issued patents.

Heinz Schwer, Ph.D., MBA, Chief Business Officer, is a serial biotechnology entrepreneur and former venture capital investor. Before joining VERAXA, he served as general partner at EMBL Ventures and previously held chief executive roles at ViraTherapeutics, Lanthio Pharma and Sloning BioTechnology, each of which was subsequently acquired by larger industry participants.

Christoph Erkel, Ph.D., Vice President of Research & Development, has more than 15 years of experience in early-stage drug discovery, with expertise spanning discovery, engineering, and preclinical development of antibodies. Prior to VERAXA, he held several positions of increasing responsibility in R&D at MorphoSys AG, where he led immuno-oncology programs focused on conditionally active T-cell engagers for the treatment of solid and hematologic tumors.

For more information, visit the company’s website at www.VERAXA.com.

NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at https://nnw.fm/VRXA https://ibn.fm/VRXA

Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising.

• Onco-Innovations is developing ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor designed to target DNA repair pathways involved in cancer survival and treatment resistance.
• The company is positioning itself as a leader in the emerging PNKP inhibitor class, a segment of the broader DNA Damage Response therapy market that is distinct from established PARP inhibitor therapies.
• Five patents protect the company’s PNKP inhibitor technology, nanoparticle delivery platform and related applications, supporting its intellectual property position as development advances.
• Through its wholly owned subsidiary Inka Health, Onco-Innovations has integrated the SynoGraph(TM) causal AI platform to support patient stratification, clinical trial design and oncology evidence generation.
• Ongoing CMC, IND-enabling and preclinical development activities are intended to support advancement of ONC010 toward planned first-in-human clinical studies.

Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) is a clinical-stage oncology company focused on advancing a new class of DNA Damage Response (“DDR”) therapies and developing artificial intelligence-driven precision oncology solutions. The company is leading the development of Polynucleotide Kinase Phosphatase (“PNKP”) inhibitors, an emerging category of DDR therapeutics designed to target DNA repair pathways involved in cancer survival and resistance. Through its dual-platform approach, Onco-Innovations combines proprietary drug development with AI-enabled technologies intended to support oncology research, clinical development, patient stratification and evidence generation.

The company’s strategy is centered on building a scalable oncology platform supported by proprietary intellectual property, strategic collaborations and integrated development capabilities. In recent years, Onco-Innovations has expanded its operational footprint through acquisitions, research partnerships and manufacturing initiatives, including the acquisition of Inka Health Corp. and its SynoGraph(TM) platform, a proprietary causal AI technology designed to support predictive oncology modeling and evidence generation. The company has also established relationships across pharmaceutical development, analytics and clinical research environments as it advances its broader oncology ecosystem.

Alongside its therapeutic and AI-focused initiatives, Onco-Innovations continues to advance manufacturing, regulatory and preclinical programs intended to support future clinical studies. The company’s stated mission is to develop cutting-edge therapies that improve patient outcomes and bring hope in the fight against cancer.

Onco-Innovations Ltd. is headquartered in Calgary, Alberta.

Products and Development Pipeline

Onco-Innovations is advancing ONC010(TM), a nanoparticle-encapsulated drug candidate built around the company’s proprietary PNKP inhibitor technology. PNKP plays a central role in repairing damaged DNA, and the company’s approach is designed to disrupt these repair mechanisms, resulting in the accumulation of DNA damage within cancer cells.

PNKP represents a novel drug target, with PNKP inhibitors emerging as a new and distinct class of DNA Damage Response cancer therapies. Inhibition of PNKP kills tumor cells by sensitizing them to radiation and DNA-damaging chemotherapies, and by exploiting tumors with certain DNA repair defects. The company’s lead program is initially focused on exploiting these repair vulnerabilities in biomarker-selected solid tumors and hematologic cancers, with future development incorporating combinations with chemotherapy or radiotherapy. In preclinical testing, PNKP inhibition is active in colorectal cancer, lung cancer, breast cancer, prostate cancer, lymphoma, leukemia, and ovarian cancer.

Five patents protect the company’s PNKP technology platform and related innovations.

A key component of ONC010 is its proprietary nanoparticle delivery system, which combines the active pharmaceutical ingredient A83B4C63 with a polymer-based micellar carrier designed to improve drug delivery to tumors. The platform was developed to address historical toxicity and delivery challenges associated with DNA Damage Response inhibitors by extending circulation time, enhancing tumor accumulation and limiting off-target exposure. Preclinical studies have demonstrated tumor reduction, increased median survival and favorable toxicity profiles in animal models, supporting the company’s ongoing efforts to advance the program toward first-in-human clinical studies.

To support clinical advancement, Onco-Innovations continues to execute an integrated Chemistry, Manufacturing and Controls (“CMC”) program in collaboration with Dalton Pharma Services while conducting pharmacokinetic and biodistribution studies with Nucro-Technics. Recent activities have included analytical method development, impurity profiling, polymer characterization, manufacturing scale-up, formulation development and validation work designed to support IND-enabling studies and future clinical readiness. The company has also established operational infrastructure in Australia to support planned Phase I development activities and regulatory progression through the Therapeutic Goods Administration pathway.

In addition to its therapeutics platform, Onco-Innovations has expanded its capabilities through the acquisition of Inka Health Corp. and its SynoGraph(TM) platform. The company describes SynoGraph(TM) as a proprietary causal AI platform designed to support prediction of oncology clinical trial outcomes, treatment efficacy, safety and adverse events through the integration of real-world data, clinical evidence and molecular insights. The platform is intended to support patient stratification, trial design, translational decision-making and evidence generation while helping reduce the time, cost and risk associated with oncology drug development. Through Inka Health, Onco-Innovations has announced collaborations involving AstraZeneca, GlaxoSmithKline and other strategic partners focused on predictive modeling, real-world evidence and AI-enabled oncology research.

Market Opportunity

Onco-Innovations is targeting opportunities across the oncology, precision medicine and DNA Damage Response (“DDR”) therapy markets. Company materials state that DDR inhibitors represented more than $7 billion in global sales during 2025, reflecting growing interest in therapies designed to disrupt cancer cells’ ability to repair damaged DNA. The company believes PNKP inhibitors represent an emerging class within the broader DDR landscape, positioning Onco-Innovations within a rapidly evolving segment of oncology drug development.

The company’s lead therapeutic program will evaluate PNKP inhibition in biomarker-selected solid tumors and hematologic cancers. Beyond monotherapy, Onco-Innovations anticipates combining its PNKP inhibitor with chemotherapy and radiation. Onco-Innovations is also actively engaged in extending its PNKP inhibitor technology and related intellectual property, and in expanding its portfolio of cancer therapies.

According to company materials, the global oncology market is projected to approach approximately $500 billion by 2032, representing projected growth of 131% over a 10-year period. The company also cites projections indicating that global cancer cases may rise by 47% by 2040, while the broader oncology market is expected to grow at a compound annual growth rate of 8.9%. A Grand View Research report projects the global precision medicine market could reach approximately $405.1 billion by 2033, growing at a compound annual growth rate of 16.99% from 2026 through 2033.

Leadership Team

Thomas O’Shaughnessy, Chief Executive Officer, brings more than 25 years of experience across healthcare, life sciences, strategy and operations. A former partner at Deloitte Canada, he previously led national health industry growth initiatives and digital health programs. He is also the founder of Carnarvon Strategies and serves as a senior advisor focused on healthcare and life sciences strategy, operational execution and value creation.

Nico Mah, Chief Financial Officer and Corporate Secretary, is a Chartered Professional Accountant with experience in auditing and public accountancy. Prior to joining Onco-Innovations, he worked at PricewaterhouseCoopers LLP from 2015 through 2023, progressing from associate to manager while supporting audit, tax and consulting activities.

Dr. Islam Mohamed, Chief Medical Officer, oversees the company’s clinical strategy, including protocol development, medical oversight and regulatory engagement activities. His role includes supporting IND-enabling initiatives and helping guide the advancement of the company’s PNKP inhibitor program into early-stage clinical development while maintaining relationships with investigators, regulators and oncology stakeholders.

Stephen M. Novak, Chief of Research and Development, leads the company’s development operations across manufacturing, preclinical activities, Chemistry, Manufacturing and Controls programs and global program execution. His background includes advancing therapeutic programs through multiple stages of development with experience in GMP and GLP oversight, regulatory readiness and coordination with CRO and CDMO partners.

For more information, visit the company’s website at OncoInnovations.com.

NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising.

• Quantum BioPharma’s LUCID-MS program is built around the unmet need for MS  therapies capable of directly protecting or restoring myelin integrity that affects the loss of mobility or control of a person’s body.
• The company announced the completion of phase 1 clinical studies involving healthy volunteers, reporting that the therapy demonstrated a favorable safety profile and was generally well tolerated.
• Quantum BioPharma reached a significant milestone in April 2026 when it announced the submission of an Investigational New Drug application to the U.S. Food and Drug Administration for LUCID-MS.

Multiple sclerosis remains one of the most challenging neurological diseases facing patients and clinicians because of its progressive nature, unpredictable course and lack of a cure. The disease affects more than 2.8 million people worldwide and approximately 1 million in the USA, and many patients continue to experience worsening disability despite the availability of numerous immune-modulating therapies. Current treatments often focus on reducing inflammation and relapse frequency but may not adequately address the underlying neurodegeneration and myelin damage that drive long-term disease progression. Against this backdrop, Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), is advancing Lucid-MS, a patented therapeutic candidate designed to target demyelination and provide neuroprotection in multiple sclerosis to address loss of mobility and function of one’s body. 

Multiple sclerosis is a chronic autoimmune and neurodegenerative disease in which the immune system attacks myelin, the protective sheath surrounding nerve fibers in the brain and spinal cord. As myelin deteriorates, communication between nerves becomes disrupted, leading to symptoms that can include fatigue, impaired mobility, cognitive dysfunction, vision problems and progressive disability. While advances in immune-targeted therapies have improved disease management for many patients, neurological damage often continues over time, creating strong demand for therapies capable of directly protecting or restoring myelin integrity.

Quantum BioPharma’s LUCID-MS program is built around this unmet need. According to the company, LUCID-MS is a patented new chemical entity that demonstrated in preclinical animal models the ability to prevent and reverse myelin degradation associated with multiple sclerosis and other neurodegenerative conditions. The company has reported on clinical tests showing a mouse regaining its ability to walk after treatment with LUCID-MS. The therapy is designed as a neuroprotective compound targeting demyelination, which differentiates it from many currently approved MS therapies that primarily focus on immune suppression rather than neuronal protection. 

The company has emphasized that LUCID-MS represents a potentially first-in-class therapeutic approach. Quantum BioPharma states that the therapy is intended to inhibit demyelination while potentially supporting remyelination and preservation of neuronal function. This mechanism may position the treatment differently within the MS therapeutic landscape, where long-term progression and neurodegeneration remain major clinical concerns despite improvements in relapse management. 

LUCID-MS has continued progressing through the clinical development process. Quantum BioPharma announced the completion of phase 1 clinical studies involving healthy volunteers and reported that the therapy demonstrated a favorable safety profile and was generally well tolerated. According to reports from NeurologyLive, the study findings indicated dose-proportional exposure and supported advancement into patient-focused clinical trials. 

The company reached another significant milestone in April 2026 when it announced the submission of an Investigational New Drug application to the U.S. Food and Drug Administration for LUCID-MS. The submission supports the company’s planned phase 2 clinical trial evaluating the efficacy, safety and tolerability of the therapy in people living with multiple sclerosis. Quantum BioPharma stated that the filing included nonclinical pharmacology and toxicology studies, along with manufacturing and quality data intended to support the transition into patient testing. 

The planned phase 2 trial is expected to focus on evaluating LUCID-MS in patients with multiple sclerosis, with the company seeking to determine whether the therapy can slow disease progression by protecting myelin from degradation. Multiple Sclerosis News Today reported that Quantum BioPharma views the therapy as a differentiated approach because it directly targets the mechanisms responsible for myelin loss rather than relying solely on immune modulation. 

Quantum BioPharma has also strengthened the operational framework supporting the program. In April 2026, the company announced a binding letter of intent with Allucent to support execution of the planned phase 2 clinical trial. The company additionally identified experienced neurological specialists to participate in the development process as it advances the program through regulatory review and clinical evaluation. 

The scientific foundation behind LUCID-MS centers on preserving myelin integrity within the central nervous system. Myelin serves as an insulating layer that enables rapid electrical communication between nerve cells. In multiple sclerosis, destruction of myelin disrupts neural signaling and contributes to progressive neurological decline. By targeting demyelination directly, LUCID-MS is intended to address a central driver of disease progression that remains difficult to fully control with many existing therapies. 

Quantum BioPharma has positioned LUCID-MS as a key component of its broader neurological disease strategy. The company’s research efforts are supported by scientific leadership with backgrounds in neurological research, pharmaceutical development and regulatory affairs, including collaboration with researchers connected to the University Health Network, Massachusetts General Hospital and Harvard Medical School. 

As the global burden of multiple sclerosis continues to grow, the need for therapies capable of protecting neurons and slowing long-term disability progression remains substantial. Quantum BioPharma’s continued advancement of LUCID-MS into phase 2 development reflects ongoing efforts within the biotechnology industry to pursue therapies that move beyond symptom management and immune modulation toward directly targeting neurodegeneration itself. With regulatory review underway and additional clinical milestones ahead, LUCID-MS represents an emerging therapeutic program within the evolving multiple sclerosis treatment landscape.

For more information, visit www.QuantumBioPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

Disseminated on behalf of Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) and may include paid advertising.

• Redwood AI is developing a proprietary AI platform designed to support drug discovery, synthesis planning, and chemical analysis across pharmaceutical, public safety, defense, and industrial-related markets.
• The company is positioned across multiple large global market opportunities, including pharmaceutical development, defense-related chemical intelligence, AI-assisted drug discovery, and CDMO infrastructure applications.
• Reactosphere combines synthesis planning, optimization workflows, sourcing intelligence, and chemical analysis capabilities within a single AI-driven platform.
• Redwood AI is advancing its AI-powered chemistry platform through research collaborations and government-supported initiatives involving organizations including UBC, NRC IRAP, Mitacs, Resilience Biosciences, Aidos Innovations, and Canadian public safety agencies.
• The company is led by a multidisciplinary team with expertise spanning artificial intelligence, chemistry, healthcare, scientific research, and data science.

Redwood AI (CSE: AIRX) (OTCQB: RDWCF) develops artificial intelligence-powered platforms focused on accelerating chemistry research and development across pharmaceutical, defense, public safety, and industrial applications. The company is working at the intersection of AI and chemistry, building tools intended to help organizations navigate increasingly complex scientific and development challenges. Redwood AI’s platforms are built on proprietary AI models and analytical infrastructure that improve as datasets and platform usage expand.

Redwood AI is positioning its technology across several emerging areas, including drug discovery, chemical development, and public safety applications tied to hazardous material analysis and chemical intelligence initiatives. Through collaborations involving academic institutions, government-supported programs, and commercial organizations, the company is advancing the use of AI-driven chemistry tools in both commercial and public-sector environments.

The company’s head office is located in Vancouver, British Columbia.

Public Safety and Defense Applications

Redwood AI is expanding its platform into hazardous material analysis, public safety, and defense-related applications. In April 2026, the company announced a collaboration with Aidos Innovations involving the development of an AI-supported analytical platform intended to assist toxic opioid detection and monitoring initiatives involving the Royal Canadian Mounted Police (“RCMP”), the Victoria Police Department, the Canada Border Services Agency, and public safety stakeholders through a British Columbia government-supported Track & Trace initiative.

The company is also advancing its Q-SAFE hazardous chemical risk classification initiative with support from the National Research Council of Canada Industrial Research Assistance Program. Redwood AI believes these initiatives demonstrate the platform’s applicability across chemical intelligence, safety monitoring, and defense-related environments.

Reactosphere

Reactosphere is Redwood AI’s proprietary AI platform designed to help organizations navigate complex chemical development workflows across pharmaceutical, industrial, public safety, and defense-related environments. By combining proprietary AI models with chemistry-focused data analysis tools, the platform is intended to support faster decision-making, improve experimental planning, and help research teams evaluate chemical pathways more efficiently.

The platform is designed to predict and optimize chemical synthesis pathways while incorporating sourcing intelligence, safety analysis, and manufacturing considerations into the evaluation process. Redwood AI states that Reactosphere’s models are trained on more than 1 billion molecules and more than 5 million chemical reactions, with expanded datasets under development through research collaborations intended to improve predictive capabilities further.

In May 2026, Redwood AI announced preliminary results from a research collaboration with the University of British Columbia aimed at expanding Reactosphere’s predictive capabilities. According to the company, the initiative increased the platform’s evaluated chemical reaction universe from approximately 4 million training examples to more than 21 million examples, supporting efforts to improve synthesis planning, route analysis, and broader chemical prediction capabilities over time.

Drug Discovery and Development

Redwood AI is positioning its platform to support AI-assisted small-molecule drug discovery and development workflows. In May 2026, the company announced a collaboration with Resilience Biosciences Inc. focused on applying Redwood’s computational chemistry, retrosynthetic analysis, and molecular design capabilities to therapeutic development programs.

The company believes its platform can help research teams evaluate chemical space more efficiently while supporting synthesis planning, candidate assessment, and early-stage development analysis. Redwood AI is also advancing platform capabilities intended to support future AI-enabled drug candidate generation initiatives.

Market Opportunity

Redwood AI is positioned across several large and expanding markets tied to defense applications, pharmaceutical development, chemical manufacturing infrastructure, and AI-assisted drug discovery. The company is targeting defense and chemical intelligence applications within the global defense spending market, which Spherical Insights estimates at approximately $2.7 trillion in 2024 and projects will reach approximately $6.38 trillion by 2035. According to Grand View Research, the global pharmaceutical market was estimated at approximately $1.74 trillion in 2025 and is projected to exceed $2.78 trillion by 2033, while the pharmaceutical CDMO market is projected to grow from approximately $197.4 billion in 2025 to approximately $392.67 billion by 2035.

Redwood AI also references the AI-enabled drug discovery market, estimated at approximately $6.93 billion in 2025 and projected to reach approximately $17.81 billion by 2035.

The company believes increasing investment in AI, advanced analytics, hazardous material detection, and security technologies is expanding demand for chemistry-focused AI platforms across government, industrial, and defense-related environments.

Leadership Team

Louis Dron, Chief Executive Officer, is a healthcare executive with experience spanning clinical science, diagnostics, health technology, and research leadership. His background includes work in hospital systems and clinical diagnostics in the United Kingdom, along with leadership roles focused on integrating real-world evidence, epidemiology, and biostatistics into healthcare decision-making. Dron has also served as an advisor to the Canadian Drug Agency and the Bill & Melinda Gates Foundation and is a graduate of the University of Manchester and the University of Leicester.

Kristian Thorlund, President & Director, is a data science and artificial intelligence entrepreneur with more than 15 years of experience across health technologies and analytics-focused businesses. He has co-founded five Canadian companies, including two multi-million-dollar exits, and has developed an extensive publication and research record in AI and data analysis. Thorlund also serves as a part-time professor at McMaster University and was previously ranked among the top 1% most cited researchers globally. He is a graduate of the University of Copenhagen and McMaster University and previously a visiting professor at Stanford.

Glenn Sammis, Head of Chemistry, is a chemistry researcher and academic with nearly two decades of experience in chemical sciences and synthesis research. He is a professor at the University of British Columbia and has secured more than $5.5 million in grants during his academic career. In addition to his research work in radical and photochemical processes, Sammis has advised more than 10 private companies on synthesis-related challenges and is a graduate of Stanford University and Harvard University.

For more information, visit the company’s website at https://redwoodai.com.

NOTE TO INVESTORS: The latest news and updates relating RDWCF are available in the company’s newsroom at https://ibn.fm/RDWCF

• MindWave Innovations recently advanced its Bitcoin treasury strategy with up to $100M PIPE and activation of 1,000 BTC, accelerating institutional adoption of AI-driven digital asset infrastructure
• The company operates at the intersection of insured custody, AI yield engines, and board-governed segregated treasury structures
• These developments reinforce MindWave’s mission: providing institutional-grade treasury infrastructure for the digital asset economy

MindWave Innovations (NYSE American: APUS) is strategically positioning itself at the forefront of a structural shift in corporate finance: the transition from static treasury holdings to intelligent, yield-generating digital asset infrastructure. As companies increasingly follow the path pioneered by MicroStrategy and newer institutional adopters, the demand for compliant, secure, and yield-optimized Bitcoin treasury systems has intensified. 

The company’s latest milestone, up to $100 million PIPE financing alongside the activation of 1,000 BTC, highlights increasing investor conviction in Bitcoin not just as a store of value, but as a productive treasury instrument when paired with institutional-grade infrastructure (ibn.fm/LFt2j). Unlike what is obtainable with traditional corporate treasuries that depend on cash equivalents or short-duration government securities yielding modest returns, MindWave’s model introduces programmable yield strategies anchored in digital markets.

At the nucleus of MindWave’s architecture is its insured custody and segregated treasury framework. Assets are held in institutional custody environments with layered insurance protections and board-controlled structures that ensure separation of strategic, operational, and custodial authority. This structure is made to meet the expectations of corporate finance teams while maintaining exposure to digital asset upside.

Beyond custody, MindWave’s AI-powered yield engine differentiates its platform in a quickly evolving ecosystem. The system dynamically allocates capital across derivatives positioning, liquidity provisioning in decentralized markets, and volatility-based trading strategies designed to extract non-directional returns from Bitcoin markets. Unlike what is obtainable with speculative trading, these strategies are structured around drawdown controls, risk parameters, and capital preservation models aligned with institutional mandates. 

Also, MindWave integrates validator node infrastructure, making it possible for corporations to participate in blockchain network validation mechanisms that generate protocol-level yield. This approach introduces a third dimension of treasury performance, operational yield derived from network participation, expanding beyond simple price appreciation.

The importance of this model becomes clearer when compared to traditional treasury instruments. While American Treasury bills and money market funds typically offer single-digit yields constrained by macroeconomic cycles, Bitcoin treasury strategies enhanced by AI-driven infrastructure introduce a hybrid return profile combining asset appreciation potential with active yield generation. However, MindWave emphasizes that such strategies are built with risk-aware architecture rather than unchecked leverage or directional exposure.

By ensuring transparent reporting systems, the company intends to tackle one of the most pressing institutional concerns: control and accountability in digital asset management. This places MindWave as not just a crypto-adjacent tech provider, but also as a treasury infrastructure partner for corporations entering the digital asset economy.

As institutional adoption of Bitcoin speeds up worldwide, MindWave Innovations is betting on a future where corporate treasuries evolve into intelligent capital systems, capable of optimizing, adapting, and generating yield in real time. For corporate finance leaders and digital asset investors alike, the company’s approach signals a potential redefinition of what treasury management looks like in the era of programmable money.

For more information, visit the company’s website at www.MindWaveDAO.com.

NOTE TO INVESTORS: The latest news and updates relating to APUS are available in the company’s newsroom at https://ibn.fm/APUS

• OTLC continues to advance its Deciparticle nanomedicine platform, with expanding international development initiatives supporting future therapeutic and commercial opportunities.
• The company’s PDAOAI ecosystem now incorporates 28 million scientific abstracts and is being deployed into real-world pharmaceutical automation applications through TechForce Robotics.
• The company is leveraging AI, nanomedicine, and automation to accelerate therapies for cancer and rare diseases.

Oncotelic Therapeutics (OTCQB: OTLC) is strategically placing itself at the nexus of precision oncology, advanced automation, and artificial intelligence. Through its PDAOAI artificial intelligence ecosystem, Deciparticle(TM) nanomedicine platform, and emerging robotics initiatives, the company is quickly building an integrated technology portfolio built to improve the way therapies are developed, manufactured, and delivered to patients suffering from some of the most difficult-to-treat diseases (ibn.fm/lU39h).

A critical aspect of the company’s strategy is its Deciparticle(TM) platform, developed through its relationship with Sapu Nano. The technology is created to address longstanding challenges associated with hydrophobic drugs, which usually suffer from poor solubility, limited bioavailability, and dose-limiting toxicities. By formulating therapeutics into ultra-small nanoparticles measuring less than 20 nanometers, Deciparticle(TM) seeks to improve intravenous delivery, enhance tissue penetration, and enable more precise tumor targeting.

The platform is advancing through multiple programs, including Sapu003, an intravenous formulation of Sapu006, a pilysorbate-free intravenous docetaxel formulation, and everolimus. According to company data, Deciparticle(TM) technology can formulate a broad range of challenging compounds while maintaining consistent nanoparticle size and stability (ibn.fm/iTfEQ). The company believes these capabilities could help create opportunities across immunology, oncology, and peptide therapeutics.

Momentum behind the platform continues to build. Recently, Sapu Nano announced an expansion of its international development strategy designed to accelerate advancement of Deciparticle-enabled therapeutic candidates and broaden potential commercialization opportunities. The initiative underscores growing confidence in the platform’s applicability across multiple drug classes while supporting Oncotelic’s objective of developing scalable solutions for difficult-to-formulate compounds.

“This platform advances beyond single-asset value to a multi-asset opportunity across oncology, immunology, and peptide therapeutics. Sapu003 is only the beginning,” said Vuong Trieu, Chief Executive Officer of Sapu Nano.

Beyond drug delivery, Oncotelic is leveraging AI to create a scalable knowledge development ecosystem. The company’s proprietary PDAOA platform recently attained a significant milestone with the successful integration of about 28 million scientific abstracts, representing a vast repository of scientific knowledge. The platform is specially designed to organize, analyze, and apply this information to support translational research, therapeutic development, and operational decision-making.

The company is now extending those capabilities into commercial applications through its jointly developed robotics platform with TechForce Robotics. By embedding scientific knowledge directly into automated workflows operating in regulated pharmaceutical environments, the platform is created to improve efficiency, cut down reliance on manual processes, and support compliance throughout manufacturing and development operations.

The collaboration recently advanced with TechForce Robotics’ formal entry into pharmaceutical automation, marking an important step toward deploying AI-enabled robotic systems within regulated life sciences environments. The initiative reflects Oncotelic’s broader vision of combining artificial intelligence, scientific knowledge management, and automation to create integrated solutions that can streamline drug development and manufacturing workflows.

“We are moving from data to real-world application,” said Dr. Vuong Trieu, Chairman and Chief Executive Officer of Oncotelic. “By embedding the totality of scientific knowledge into robotics, we can look to transform how drugs are developed and produced, not just for us, but for the broader industry.”

Initial deployments are expected as the company pushes toward the broader commercialization and prepares to scale production capabilities to support expected demand.

These technology initiatives perfectly complement Oncotelic’s therapeutic pipeline, which focuses on areas of substantial unmet need, including orphan oncology indications.

The company’s leading candidate, OT-101, targets TGF-beta signaling and has received orphan-focused designations for Diffuse Intrinsic Pontine Glioma (“DIPG”), a devastating pediatric brain cancer with limited treatment options.

Taken together, the continued advancement of the Deciparticle platform, the expansion of international development initiatives through Sapu Nano, and the progression of AI-powered pharmaceutical automation with TechForce Robotics highlight Oncotelic’s strategy of building value across multiple complementary technologies. While OT-101 and the company’s oncology pipeline remain central to its therapeutic ambitions, the combination of AI, advanced nanomedicine, and robotics positions OTLC to participate in several high-growth segments of healthcare innovation, potentially creating multiple pathways for future commercialization and long-term value creation.

For more information, visit the company’s website at www.Oncotelic.com.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising.

• MindBio Therapeutics is developing AI-powered voice analysis technology designed to detect drug and alcohol impairment from short speech samples.
• The platform analyzes more than 140 acoustic markers and has been trained on a dataset exceeding 50 million data points.
• Mining operations in South America represent the company’s initial commercial focus, where workforce safety and high-volume screening requirements create operational challenges.
• Potential applications extend beyond mining into aviation, construction, law enforcement, call centers, transportation, and mental health settings.
• The global alcohol and drug testing devices market is projected to grow from approximately $2.5 billion in 2025 to $4.2 billion by 2033.
• MindBio’s approach seeks to provide a faster, less invasive alternative to traditional breath, saliva, urine and laboratory-based testing methods.

Workplace impairment testing remains an essential component of risk management across many industries, but the methods used today have changed relatively little over the past several decades. Employers continue to rely heavily on breathalyzers, saliva tests, urine screening and laboratory analysis to identify alcohol and drug impairment. While effective, these methods can be expensive, time-consuming and difficult to scale across large workforces. That challenge is becoming increasingly relevant as regulators and employers place greater emphasis on workplace safety, compliance and operational efficiency.

Against this backdrop, MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF), a biotechnology company, is developing a technology platform that takes a different approach. The company has spent several years conducting drug and alcohol research while building artificial intelligence and machine-learning models designed to estimate intoxication levels through speech analysis. Rather than requiring biological samples, the platform analyzes voice recordings captured through standard microphones.

According to the company, its system evaluates more than 140 acoustic markers and has been trained using more than 50 million data points collected through extensive research programs. The objective is straightforward: identify measurable changes in speech associated with alcohol or drug impairment and generate an assessment in real time.

The commercial opportunity surrounding that capability may be substantial. The global alcohol and drug testing devices market is expected to expand from approximately $2.5 billion in 2025 to $4.2 billion by 2033 as employers adopt new safety technologies and regulatory requirements continue to evolve (https://ibn.fm/88jXn). 

The need extends well beyond regulatory compliance. In industries such as mining, aviation, transportation and construction, impairment screening is often mandated because employees operate heavy equipment, work in hazardous environments or perform safety-sensitive tasks where mistakes can carry significant consequences.

Large organizations may process hundreds or thousands of workers each day, creating logistical challenges when traditional testing methods are used. MindBio believes artificial intelligence can help address that issue. The company is developing Edge AI kiosk systems designed to collect short voice samples from workers entering a facility. Within seconds, the system could potentially identify indicators of impairment and flag individuals requiring further evaluation.

This process would replace traditional screening models that are time consuming, unhygienic and expensive on a per test basis. This new category changing testing solution may function as a rapid screening layer that helps employers allocate resources more efficiently while reducing operational bottlenecks.

Mining has emerged as the company’s initial target market. Many mining operations, particularly in South America, involve remote sites, rotating workforces and physically demanding environments where safety monitoring is critical and drug and alcohol consumption is a major problem. Traditional testing programs can become expensive and administratively burdensome when deployed across large numbers of employees.

MindBio has indicated that field testing of its kiosk technology is expected during 2026, providing an important opportunity to evaluate performance in real-world industrial settings.

The potential market extends well beyond mining. The company has previously highlighted aviation and construction as logical applications because both sectors already operate within regulatory frameworks that require impairment management and workforce monitoring. In aviation, rapid screening tools could potentially assist operators managing large employee populations across multiple facilities. Construction companies face similar challenges, particularly on large infrastructure projects where contractors, subcontractors and temporary workers may need to be screened efficiently.

Another area attracting attention is call-center operations. While call centers are not typically associated with physical safety risks, employers increasingly monitor employee performance, wellness and productivity. Because communication occurs almost entirely through speech, voice analytics may provide additional insights regarding impairment, fatigue or behavioral changes.

Mental health and healthcare settings present another potential use case. Voice analysis has increasingly been studied as a tool for identifying changes in emotional state, stress levels and cognitive function. While MindBio’s primary focus remains intoxication detection, the broader field of speech analytics continues to attract interest from researchers exploring non-invasive health monitoring technologies.

Law enforcement may also represent a future opportunity. Officers frequently encounter situations where immediate assessment of impairment would be valuable, yet laboratory testing may not be readily available. A rapid voice-based screening tool could potentially serve as an additional assessment mechanism.

What differentiates MindBio from many technology companies entering workplace safety markets is the foundation of its research. The company’s machine-learning models are derived from years of drug and alcohol studies, creating datasets specifically designed to examine the relationship between speech patterns and impairment. Management believes that proprietary data may become a significant competitive advantage as artificial intelligence applications expand across healthcare and enterprise markets.

For more information, visit the company’s website at www.MindBioTherapeutics.com. 

NOTE TO INVESTORS: The latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF

Disseminated on behalf of Numa Numa Resources Inc. and may include paid advertisements.

• Today many mining projects are designed with a wider development mandate, recognizing that infrastructure can generate benefits extending well beyond the life of a mine.
• Numa Numa Resources has positioned infrastructure development as a central component of its strategy.
• The company’s infrastructure efforts are occurring alongside agreements with landowners connected to the Panguna resource area.

Modern mining projects are no longer judged solely by the minerals they produce. Increasingly, companies are being evaluated on the roads they build, the power systems they create and the long-term economic opportunities they leave behind. In Bougainville, Numa Numa Resources is pursuing this broader approach, combining resource development ambitions with infrastructure investments designed to reconnect communities and support future growth.

The relationship between mining and infrastructure has existed for generations, but the nature of that relationship has evolved significantly. Historically, mining companies often built infrastructure primarily to support extraction activities. Roads, railways, ports and power facilities were constructed to move equipment and transport ore. Today, however, many mining projects are designed with a wider development mandate, recognizing that infrastructure can generate benefits extending well beyond the life of a mine.

This shift reflects both practical business considerations and changing stakeholder expectations. The World Bank has noted that infrastructure associated with extractive industries can contribute to broader economic development when planned and managed effectively, helping improve transportation networks, energy access and connectivity for surrounding communities. Better infrastructure can reduce operating costs for mining companies while simultaneously creating new opportunities for local businesses, healthcare providers, schools and residents.

The importance of infrastructure is particularly evident in remote regions where transportation and energy access remain limited. Studies show that infrastructure investments are often critical components of resource development projects because they support both industrial activity and wider economic participation. Roads can connect isolated populations to markets and services, while power systems can support new industries that continue operating long after mining activities conclude.

Lessons learned from past mining projects have also influenced this evolution. In regions where mining operations were associated with social conflict, environmental concerns or disputes over economic benefits, communities increasingly expect developers to demonstrate broader commitments to local development. Industry organizations such as the International Council on Mining and Metals emphasize the importance of social performance and community engagement as essential elements of modern mining operations.

Bougainville provides a compelling example of why these issues matter. The region’s history is closely tied to the Panguna Mine, which began production in 1972 and became one of the world’s largest copper and gold mines. At its peak, the operation generated a significant portion of Papua New Guinea’s export revenue, according to research published by the Australian National University’s Devpolicy program. However, disputes involving environmental impacts, land ownership and revenue distribution contributed to tensions that ultimately helped fuel the Bougainville conflict, which lasted from 1988 to 1998.

In the years since the Bougainville Peace Agreement was signed in 2001, the region has focused on rebuilding institutions, infrastructure and economic opportunities. Any future resource development efforts must navigate this history while demonstrating how projects can create value for local communities.

Within this context, Numa Numa Resources has positioned infrastructure development as a central component of its strategy. According to the company, one of its most significant initiatives is the construction of the first east-west road across Bougainville’s mountainous central mining district since before the civil conflict. The project is designed not only to support potential mining activities but also to improve transportation access across an area that has remained difficult to traverse for decades.

For isolated communities, transportation infrastructure can have transformative effects. Roads can reduce travel times, improve access to healthcare and education, lower the cost of goods and services and facilitate economic activity. In many developing regions, transportation corridors become catalysts for broader growth by enabling agricultural production, trade and entrepreneurship.

Numa Numa’s infrastructure efforts are occurring alongside agreements with landowners connected to the Panguna resource area. For example, since the Panguna area remains off the grid in the aftermath of the civil conflict, the company was authorized by the government to conduct feasibility studies for the development and construction of a renewable energy based (hydroelectric, solar, and battery power), integrated electric utility to bring electricity back to the region. The company is working with customary landowners to support future development of what it describes as an estimated $100 billion copper and gold resource opportunity. While the ultimate economic value of any mineral deposit depends on commodity prices, technical assessments and development outcomes, the scale of the resource has long attracted international attention.

The company’s emphasis on collaboration reflects broader trends in second-generation mining projects. Rather than focusing exclusively on extraction, developers increasingly recognize that long-term success depends on building trust, creating shared economic benefits and investing in assets that communities can continue using long after mining operations have ended.

In Bougainville, that philosophy may prove particularly important. The region’s future will likely be shaped not only by the minerals beneath the ground but also by the infrastructure above it. Roads, transportation networks and community investments can provide lasting value that extends beyond resource production itself.

As a result, projects such as those being pursued by Numa Numa Resources illustrate how modern mining is evolving. The focus is no longer simply on what can be extracted, but on what can be built. For Bougainville, infrastructure development may ultimately become one of the most important legacies of resource investment, helping connect communities, expand economic opportunity and support the region’s long-term development goals.

For more information, visit www.NumaNumaResources.com. 

NOTE TO INVESTORS: The latest news and updates relating to Numa Numa are available in the company’s newsroom at https://ibn.fm/NUMA

Disseminated on behalf of Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF) and may include paid advertising.

• Traditionally, many significant investment opportunities in the space industry were only accessible to venture capital and institutional investors, leaving retail investors unable to participate.
• However, Planet Ventures Inc. is changing this, as the company provides shareholders with indirect exposure to private space and aerospace companies through a publicly traded investment vehicle.
• A variety of companies stretch under Planet Ventures’ belt, including areas like software, energy, robotics, emerging applications, and infrastructure.

The commercial space economy is entering a new phase of growth. What was once dominated by government agencies is rapidly evolving into a global industry encompassing satellite communications, orbital infrastructure, artificial intelligence, robotics, energy systems, and even lunar development. With industry forecasts projecting the space economy is projected to surpass $1 trillion in value over the coming decades, investors are increasingly looking for ways to participate in this transformation.

Yet many of the most promising opportunities remain inaccessible to everyday investors. Historically, exposure to emerging space companies has largely been reserved for venture capital firms, institutional investors, and private funding networks, leaving retail investors with limited options to gain meaningful participation in the sector’s growth.

Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF) is helping bridge that gap. As a publicly traded investment issuer focused on the space and aerospace industries, the company provides investors with indirect exposure to a portfolio of private and early-stage businesses developing technologies that could help shape the future of the next frontier.

Planet Ventures’ strategy centers on identifying innovative companies operating across key segments of the emerging space economy and allocating capital to businesses positioned to benefit from long-term industry expansion. Through this approach, shareholders gain access to opportunities spanning orbital infrastructure, energy systems, artificial intelligence, robotics, and lunar development through a single public-market vehicle.

The company’s portfolio reflects several of the most important themes driving the next generation of space commercialization. Planet Ventures has invested in Relativity Space, a launch infrastructure company led by former Google CEO Eric Schmidt; Mantis Space, which is developing what it describes as the world’s first orbital power grid; and Antaris Inc., whose AI-powered software platform is designed to simplify satellite constellation design, simulation, and operations.

The company has also  made an investment into Galactic Resource Utilization Space Inc., which is pursuing lunar infrastructure and space tourism initiatives, including plans for a lunar hotel; General Astronautics, a developer of autonomous robotics systems for microgravity research and development; and Lux Aeterna, which is building a fully reusable satellite platform designed to support future space operations.

Collectively, these investments provide exposure to several of the technologies expected to underpin the expanding commercial space ecosystem. From orbital energy generation and AI-driven mission management to robotics and lunar infrastructure, Planet Ventures is building a portfolio aligned with the industry’s long-term evolution.

Leading the effort is CEO Etienne Moshevich alongside Executive Director Desmond Balakrishnan and a team of experienced professionals spanning capital markets, finance, technology, and business development. The company recently strengthened its space-focused investment expertise with the appointment of Dr. Bora Uygun as Head of Space Investments. A recognized entrepreneur and active angel investor, Uygun brings extensive experience across aerospace, artificial intelligence, telecommunications, and fintech.

As commercial activity in orbit continues to expand and private capital increasingly drives innovation beyond Earth, Planet Ventures offers retail investors a rare opportunity to gain exposure to private companies operating at the forefront of the space economy through a publicly traded investment platform.

For more information, visit www.PlanetVenturesInc.com.

NOTE TO INVESTORS: The latest news and updates relating to PNXPF are available in the company’s newsroom at https://ibn.fm/PNXPF

Disclaimer

Investor Brand Network (“We” or “Us”) are not securities dealers or brokers, investment advisers or financial advisers, and you should not rely on the information herein as investment advice. Planet Ventures Inc. will make aggregate payments of $100,000  to us to provide marketing services for a term of 1 year. This article is informational only and is solely for use by prospective investors in determining whether to seek additional information. This does not constitute an offer to sell or a solicitation of an offer to buy any securities. Our stock profiles are intended to highlight certain companies for your further investigation; they are not stock recommendations or constitute an offer or sale of the referenced securities. The securities issued by the companies we profile should be considered high risk; if you do invest despite these warnings, you may lose your entire investment. Please do your own research before investing, including reading the companies’ SEDAR+ and SEC filings, press releases, and risk disclosures. 

Forward-Looking Statements

This document contains forward-looking statements within the meaning of applicable securities legislation. Such statements include, without limitation, statements regarding: Planet Ventures’ investment strategy and objectives; anticipated developments in the commercial space industry, including the growth of orbital energy and space robotics markets; the projected growth of the global space economy; Planet Ventures’ expectations regarding the strategic importance of its investments in Mantis Space and General Astronautics; the anticipated role of orbital energy technologies and robotic servicing systems in future in-orbit operations; and the potential for these technologies to become foundational to the next generation of commercial space activity.

Forward-looking statements are not guarantees of future performance. Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements contained in this document are made as of the date hereof and Planet Ventures undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws.

Risk Factors

Investing in Planet Ventures and its portfolio companies involves a high degree of risk. The following is a summary of key risk factors. This is not an exhaustive list, and additional risks may exist that are not currently known:

• Early-Stage Investment Risk. Portfolio companies have limited operating histories and are pre-revenue. Investments are speculative and may result in a total loss of capital.
• Technology Risk. The orbital energy and lunar habitation technologies underlying the Company’s investments are unproven at commercial scale and may not be successfully developed or deployed.
• Regulatory Risk. Space sector operations require licenses and approvals from domestic and international regulatory bodies. Failure to obtain or maintain these could materially delay or prevent operations.
• Market Risk. Commercial demand for in-space power systems and lunar services has not been established at scale. Projected market growth may not be realized within anticipated timeframes.
• Liquidity Risk. Investments in private, early-stage companies are illiquid. There is no guarantee of a market for these securities or the ability to exit on favorable terms.
• Capital Risk. Portfolio companies may require additional funding that may not be available, or may be available only on dilutive or restrictive terms.
• Macroeconomic and Geopolitical Risk. Adverse macroeconomic conditions or geopolitical developments could disrupt the Company’s investment strategy or the operations of portfolio companies.
• Key Personnel Risk. The Company’s performance depends in part on retaining key personnel and advisors. Loss of key individuals could adversely affect the Company’s operations and investment activities